Report Detail
Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026
- RnM3398217 |
- 09 October, 2020 |
- Global |
- 93 Pages |
- QYResearch |
- Other
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Scope and Market Size
Non-Alcoholic Steatohepatitis (NASH) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Market segment by Application, split into
Hospital Pharmacy
Online Provider
Retail Pharmacy
Based on regional and country-level analysis, the Non-Alcoholic Steatohepatitis (NASH) Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2026
- 1.2.2 Vitamin E & Pioglitazone
- 1.2.3 Obeticholic Acid (OCA)
- 1.2.4 Elafibranor
- 1.2.5 Selonsertib & Cenicriviroc
- 1.3 Market by Application
- 1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
- 1.3.2 Hospital Pharmacy
- 1.3.3 Online Provider
- 1.3.4 Retail Pharmacy
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2015-2026)
- 2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
- 2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
- 2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2015-2020)
- 2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
- 2.3.1 Market Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Market Size
- 3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2015-2020)
- 3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2015-2020)
- 3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
- 3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
- 3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
- 3.5 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Area Served
- 3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
- 3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type (2015-2026)
- 4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2015-2020)
- 4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2021-2026)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application (2015-2026)
- 5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2015-2020)
- 5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2021-2026)
6 North America
- 6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
- 6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
- 6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
- 6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
- 6.4.1 United States
- 6.4.2 Canada
7 Europe
- 7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
- 7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
- 7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
- 7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia
- 7.4.6 Nordic
- 7.4.7 Rest of Europe
8 China
- 8.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
- 8.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
- 8.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
- 8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2015-2020)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 Southeast Asia
- 8.4.5 India
- 8.4.6 Australia
- 8.4.7 Rest of Asia-Pacific
9 Japan
- 9.1 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
- 9.2 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
- 9.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
- 9.4 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
- 9.4.1 Mexico
- 9.4.2 Brazil
10 Southeast Asia
- 10.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
- 10.2 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
- 10.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
- 10.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
- 10.4.1 Turkey
- 10.4.2 Saudi Arabia
- 10.4.3 UAE
- 10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
- 11.1 AstraZeneca
- 11.1.1 AstraZeneca Company Details
- 11.1.2 AstraZeneca Business Overview
- 11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020))
- 11.1.5 AstraZeneca Recent Development
- 11.2 Conatus Pharmaceuticals
- 11.2.1 Conatus Pharmaceuticals Company Details
- 11.2.2 Conatus Pharmaceuticals Business Overview
- 11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.2.5 Conatus Pharmaceuticals Recent Development
- 11.3 Enzo Biochem
- 11.3.1 Enzo Biochem Company Details
- 11.3.2 Enzo Biochem Business Overview
- 11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.3.5 Enzo Biochem Recent Development
- 11.4 Galmed Pharmaceuticals
- 11.4.1 Galmed Pharmaceuticals Company Details
- 11.4.2 Galmed Pharmaceuticals Business Overview
- 11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.4.5 Galmed Pharmaceuticals Recent Development
- 11.5 Genfit
- 11.5.1 Genfit Company Details
- 11.5.2 Genfit Business Overview
- 11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.5.5 Genfit Recent Development
- 11.6 Gilead
- 11.6.1 Gilead Company Details
- 11.6.2 Gilead Business Overview
- 11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.6.5 Gilead Recent Development
- 11.7 Horizon Pharma
- 11.7.1 Horizon Pharma Company Details
- 11.7.2 Horizon Pharma Business Overview
- 11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.7.5 Horizon Pharma Recent Development
- 11.8 Immuron
- 11.8.1 Immuron Company Details
- 11.8.2 Immuron Business Overview
- 11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.8.5 Immuron Recent Development
- 11.9 Intercept Pharmaceuticals
- 11.9.1 Intercept Pharmaceuticals Company Details
- 11.9.2 Intercept Pharmaceuticals Business Overview
- 11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.9.5 Intercept Pharmaceuticals Recent Development
- 11.10 Novo Nordisk
- 11.10.1 Novo Nordisk Company Details
- 11.10.2 Novo Nordisk Business Overview
- 11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
- 11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
- 11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
Summary:
Get latest Market Research Reports on Non-Alcoholic Steatohepatitis (NASH) Drugs . Industry analysis & Market Report on Non-Alcoholic Steatohepatitis (NASH) Drugs is a syndicated market report, published as Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
